Antiepileptic Drug Market: Current Analysis and Forecast (2021-2027)

Antiepileptic Drug Market: Current Analysis and Forecast (2021-2027)

Global Antiepileptic Drug Market is anticipated to grow with an elevated CAGR of around 2% over the forecast period (2021-2027). Antiepileptic drugs are the category of drugs developed for the treatment of asymptomatic and idiopathic symptoms of epilepsy and seizures.

As per WHO, epilepsy accounts for a significant proportion of the world’s disease burden, affecting around 50 million people worldwide. The estimated proportion of the general population with active epilepsy (i.e. continuing seizures or with the need for treatment) at a given time is between 4 and 10 per 1000 people. Thus, the rising prevalence of central nervous system disorders coupled with the rising incidence of congenital abnormalities or genetic conditions with associated brain malformations; are expected to drive the demand for efficient diagnosis and treatment of epilepsy. Thus, supporting antiepileptic drug market growth. Furthermore, the new drug approval and the collaborations of the government and private organizations are further expected to contribute significantly to the antiepileptic drug market’s growth.

Some of the major players operating in the market are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Zogenix, and Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, and Eisai Co., among others. Several M&As along with partnerships have been undertaken by these players to develop new and advanced antiepileptic drugs.

Insights Presented in the Report
"Amongst Drug Class, Third generation segment expected to hold a major share during the forecast period.”

Based on drug class, the market is classified into first generation, second generation, and the third generation. The second-generation segment accounted for a significant market share in 2020. The presence of the different classes of the drugs with the improved efficacy and specificity was responsible for significant market share in that year. However, during the forecast period, the third-generation drug class is predicted to have the fastest growth in the anti-epileptic drug market this is mainly due to the increased global focus on the new drug development and frequent drug launches of the category. For instance, In 2021, Alkem laboratories launched an antiepileptic drug named Brivasure that suppresses abnormal electrical activity in the brain.
"Amongst distribution channels, online pharmacies segment holds the major share”

Based on distribution channels, the market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. The online pharmacies category is anticipated to grow at a rapid rate in the upcoming years. This is due to the rising prevalence of internet penetration and growing government focus and investments in new-age start-ups in the digital space, especially in developing countries like India, Mexico, and Brazil. For instance, Netmeds was founded in 2015 and reached US$ 1.8 million by 2019.
"North America represents one of the largest markets of Antiepileptic Drug market”

For a better understanding of the market dynamics of the Antiepileptic Drug market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America dominated the antiepileptic drug industry. This can be mainly due to the presence of a well-established healthcare infrastructure coupled with increasing investments from private organizations and public associations for the development of effective treatment for diseases like epilepsy. Furthermore, the presence of market players and frequent product launches in the region significantly contributes to the considerable market share of the region. In June 2021, Glenmark Pharma launched the anti-epileptic drug Rufinamide in the US market.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts
• The report presents a quick review of overall industry performance at one glance
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
• The study comprehensively covers the market across different segments
• Deep dive regional level analysis of the industry